← Study Library
Review · 2023
Preclinicalcounts toward this tierPentosan Polysulfate Affords Pleotropic Protection to Multiple Cells and Tissues
Smith MM, Melrose J · Pharmaceuticals (Basel)
Preclinicalcounts toward this tier
Modern mechanism catalogue: decades of clinical deployment in cystitis and painful bowel disease, protease inhibition in cartilage and disc, complement and coagulation regulation, hyaluronan stimulation, suppression of osteocyte nerve-growth-factor production (a proposed OA-pain mechanism), and clearance of lipid from subchondral blood vessels.
- Population
- Narrative review of PPS biology across tissues
- Intervention
- n/a
- Comparator
- n/a
- Limitations
- One author is clinical research director at Arthropharm, a PPS company, and the other has taken its consultancy fees, disclosed in the acknowledgements while the conflict statement declares none; a mechanism catalogue that cites a single case report as its human bone-marrow-lesion evidence, not an outcomes assessment.
Cited by
1 entry references this study
- Pentosan polysulfate (PPS)PROM.
Peptides → Clinically studied
Evidence for that entry
Promising